Mankind pharma ipo gmp

Mankind Pharma latest IPO GMP Today is ₹121(+/-), last updated on May 9th 2023 10:18 AM. Given at the price band of 1080, the estimated listing price for the Mankind Pharma IPO is ₹1201 (cap price + today's GMP). The expected gain/loss per share in terms of percentage is 11.20%.• Mankind Pharma IPO Retail Subject to Sauda: ₹950 We update GMP on daily basis and based on the last 25 sessions grey market activities, Today's IPO GMP trend indicates Upside and expects a strong listing. With this, retail investors should apply in this IPO with full force. The lowest GMP is recorded at ₹28 while the highest GMP is ₹140. Stay tuned with us to know the day-by-day Mankind Pharma IPO GMP Performance along with its expected listing price. Mankind Pharma Day-wise IPO GMP Trend GMP Date GMP S2S Estimated Listing Price Last Updated Time 09-05-2023 ₹121 950 ₹1201 (11.20%) 9-May-2023 09:18:16 AM 08-05-2023 ₹140 950 ₹1220 (12.96%) 8-May-2023 07:33:49 PM 07-05-2023 ₹113 950 ₹1193 (10.46%) 7-May-2023 08:00:08 AM 06-05-2023 ₹113 950 ₹1193 (10.46%) 6-May-2023 06:04:00 PM 05-05-2023 ₹92 950 ₹1172 (8.52%) 5-May-2023 05:08:14 PM 04-05-2023 ₹103 950 ₹1183 (9.54%) 4-May-2023 10:00:40 PM 03-05-2023 ₹79 950 ₹1159 (7.31%) 3-May-2023 04:51:17 PM 02-05-2023 ₹82 950 ₹1162 (7.59%) 2-May-2023 05:06:48 PM 01-05-2023 ₹96 950 ₹1176 (8.89%) 1-May-2023 05:25:00 PM 30-04-2023 ₹88 550 ₹1168 (8.15%) 30-Apr-2023 11:05:48 PM 29-04-2023 ₹83 550 ₹1163 (7.69%) 29-Apr-2023 05:15:22 PM 28-04-2023 ₹84 550 ₹1164 (7.78%) 28-...

Under the OFS, promoters Ramesh Juneja, Rajeev Juneja and Sheetal Arora will offload shares. Since the IPO is completely an OFS, the company will not receive any net proceeds from the issue and the entire amount will go to the selling shareholders. At the upper end of the price band, the IPO size is estimated at Rs 4,326 crore and the company is seeking a valuation of Rs 43,264 crore. It has a pan-India marketing presence and operates 25 manufacturing facilities across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D centre with four units located at IMT Manesar, Gurugram and Thane. At the higher end of the price band, the shares of Mankind Pharma are valued at 30x FY22 EPS. According to Sharekhan, pharma companies on an average quote a P/E of 25x/22x FY24e/FY25e. The brokerage expects the company’s strong set of brands, focused approach to its chronic portfolio via recent acquisitions, launches and differentiated pipeline products to be key positives. The company has posted a net profit of Rs 996 crore for the nine months ended December 2022 period, which is down from Rs 1,243 crore in the same period of preceding year. The company's revenue from operations for the same period rose nearly 11% to Rs 6,697 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) Don’t miss out on ET Prime stories! Get your daily dose...

Mankind Pharma IPO: After closure of three days subscription on 27th April 2023, investors and market observers are eager waiting for Mankind Pharma IPO allotment date, which is most likely on 3rd May 2023. As per the Mankind Pharma IPO subscription status, the public issue received rave response from the QIB segment investors but it failed to get fully subscribed in retail segment. However, grey market is undeterred by these developments as secondary market has been in bull trend for last six straight sessions. Mankind Pharma IPO GMP today Market observers said that despite Mankind Pharma IPO failed to get subscribed 100 per cent in retail portion, strong secondary market mood has lifted the morale of grey market. Mankind Pharma IPO grey market premium (GMP) today is ₹85, which is ₹25 higher from its Friday GMP of ₹60. They said that uptrend in Mankind Pharma IPO GMP can be expected further when market opens on Monday as secondary market is in highly bullish mode as all three key benchmark indices — Nifty, Sensex and Bank Nifty — have breached their recent swing high levels and they are expected to lift the moral of unlisted stock market as well. What this GMP mean? Market observers went on to add that ₹85, which means grey market is expecting that Mankind Pharma IPO listing price would be around ₹1145 ( ₹1080 + ₹85), which is near 8 per cent higher from Mankind Pharma IPO price band of ₹10286 to ₹1080 per equity share. Market observers maintained that grey market is sign...

Synopsis Mankind Pharma's initial public offering (IPO), which will close on January 19, has been subscribed by 32% on Day 2 with non-institutional investors and qualified institutional buyers subscribing the most. Retail investors' quota had 16% bids. Nine brokerages recommended the issue, saying that growth opportunities outweigh concerns about high valuation. Mankind Pharma has raised around Rs 1,297 crore by allocating 1.2 crore equity shares to 77 anchor investors, which include Goldman Sachs, Canada Pension Plan and Government of Singapore. At the higher end of the price band, Mankind Pharma valued at 30x FY22 EPS. The IPO, which is completely an offer for sale (OFS), will close tomorrow. The price band is at Rs 1024-1080 and investors can bid for 13 shares in one lot. Nine brokerages have given "subscribe" recommendations to the issue, with some of them seeing the potential in the long term. Analysts say the growth opportunities outweigh the concerns around not-so-cheap valuations. Mankind Pharma is the fourth-largest Indian pharmaceutical company in terms of domestic sales and third largest in terms of sales volume for moving annual total as of December 2022. It has a pan-India marketing presence and operates 25 manufacturing facilities across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D centre with four units located at IMT Manesar, Gurugram and Thane. At the higher end of the price band, the shares o...

Synopsis Mankind Pharma's initial public offering (IPO), which will close on January 19, has been subscribed by 32% on Day 2 with non-institutional investors and qualified institutional buyers subscribing the most. Retail investors' quota had 16% bids. Nine brokerages recommended the issue, saying that growth opportunities outweigh concerns about high valuation. Mankind Pharma has raised around Rs 1,297 crore by allocating 1.2 crore equity shares to 77 anchor investors, which include Goldman Sachs, Canada Pension Plan and Government of Singapore. At the higher end of the price band, Mankind Pharma valued at 30x FY22 EPS. The IPO, which is completely an offer for sale (OFS), will close tomorrow. The price band is at Rs 1024-1080 and investors can bid for 13 shares in one lot. Nine brokerages have given "subscribe" recommendations to the issue, with some of them seeing the potential in the long term. Analysts say the growth opportunities outweigh the concerns around not-so-cheap valuations. Mankind Pharma is the fourth-largest Indian pharmaceutical company in terms of domestic sales and third largest in terms of sales volume for moving annual total as of December 2022. It has a pan-India marketing presence and operates 25 manufacturing facilities across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D centre with four units located at IMT Manesar, Gurugram and Thane. At the higher end of the price band, the shares o...

Mankind Pharma latest IPO GMP Today is ₹121(+/-), last updated on May 9th 2023 10:18 AM. Given at the price band of 1080, the estimated listing price for the Mankind Pharma IPO is ₹1201 (cap price + today's GMP). The expected gain/loss per share in terms of percentage is 11.20%.• Mankind Pharma IPO Retail Subject to Sauda: ₹950 We update GMP on daily basis and based on the last 25 sessions grey market activities, Today's IPO GMP trend indicates Upside and expects a strong listing. With this, retail investors should apply in this IPO with full force. The lowest GMP is recorded at ₹28 while the highest GMP is ₹140. Stay tuned with us to know the day-by-day Mankind Pharma IPO GMP Performance along with its expected listing price. Mankind Pharma Day-wise IPO GMP Trend GMP Date GMP S2S Estimated Listing Price Last Updated Time 09-05-2023 ₹121 950 ₹1201 (11.20%) 9-May-2023 09:18:16 AM 08-05-2023 ₹140 950 ₹1220 (12.96%) 8-May-2023 07:33:49 PM 07-05-2023 ₹113 950 ₹1193 (10.46%) 7-May-2023 08:00:08 AM 06-05-2023 ₹113 950 ₹1193 (10.46%) 6-May-2023 06:04:00 PM 05-05-2023 ₹92 950 ₹1172 (8.52%) 5-May-2023 05:08:14 PM 04-05-2023 ₹103 950 ₹1183 (9.54%) 4-May-2023 10:00:40 PM 03-05-2023 ₹79 950 ₹1159 (7.31%) 3-May-2023 04:51:17 PM 02-05-2023 ₹82 950 ₹1162 (7.59%) 2-May-2023 05:06:48 PM 01-05-2023 ₹96 950 ₹1176 (8.89%) 1-May-2023 05:25:00 PM 30-04-2023 ₹88 550 ₹1168 (8.15%) 30-Apr-2023 11:05:48 PM 29-04-2023 ₹83 550 ₹1163 (7.69%) 29-Apr-2023 05:15:22 PM 28-04-2023 ₹84 550 ₹1164 (7.78%) 28-...

Under the OFS, promoters Ramesh Juneja, Rajeev Juneja and Sheetal Arora will offload shares. Since the IPO is completely an OFS, the company will not receive any net proceeds from the issue and the entire amount will go to the selling shareholders. At the upper end of the price band, the IPO size is estimated at Rs 4,326 crore and the company is seeking a valuation of Rs 43,264 crore. It has a pan-India marketing presence and operates 25 manufacturing facilities across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D centre with four units located at IMT Manesar, Gurugram and Thane. At the higher end of the price band, the shares of Mankind Pharma are valued at 30x FY22 EPS. According to Sharekhan, pharma companies on an average quote a P/E of 25x/22x FY24e/FY25e. The brokerage expects the company’s strong set of brands, focused approach to its chronic portfolio via recent acquisitions, launches and differentiated pipeline products to be key positives. The company has posted a net profit of Rs 996 crore for the nine months ended December 2022 period, which is down from Rs 1,243 crore in the same period of preceding year. The company's revenue from operations for the same period rose nearly 11% to Rs 6,697 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) Don’t miss out on ET Prime stories! Get your daily dose...

Mankind Pharma IPO: After closure of three days subscription on 27th April 2023, investors and market observers are eager waiting for Mankind Pharma IPO allotment date, which is most likely on 3rd May 2023. As per the Mankind Pharma IPO subscription status, the public issue received rave response from the QIB segment investors but it failed to get fully subscribed in retail segment. However, grey market is undeterred by these developments as secondary market has been in bull trend for last six straight sessions. Mankind Pharma IPO GMP today Market observers said that despite Mankind Pharma IPO failed to get subscribed 100 per cent in retail portion, strong secondary market mood has lifted the morale of grey market. Mankind Pharma IPO grey market premium (GMP) today is ₹85, which is ₹25 higher from its Friday GMP of ₹60. They said that uptrend in Mankind Pharma IPO GMP can be expected further when market opens on Monday as secondary market is in highly bullish mode as all three key benchmark indices — Nifty, Sensex and Bank Nifty — have breached their recent swing high levels and they are expected to lift the moral of unlisted stock market as well. What this GMP mean? Market observers went on to add that ₹85, which means grey market is expecting that Mankind Pharma IPO listing price would be around ₹1145 ( ₹1080 + ₹85), which is near 8 per cent higher from Mankind Pharma IPO price band of ₹10286 to ₹1080 per equity share. Market observers maintained that grey market is sign...

Synopsis Mankind Pharma's initial public offering (IPO), which will close on January 19, has been subscribed by 32% on Day 2 with non-institutional investors and qualified institutional buyers subscribing the most. Retail investors' quota had 16% bids. Nine brokerages recommended the issue, saying that growth opportunities outweigh concerns about high valuation. Mankind Pharma has raised around Rs 1,297 crore by allocating 1.2 crore equity shares to 77 anchor investors, which include Goldman Sachs, Canada Pension Plan and Government of Singapore. At the higher end of the price band, Mankind Pharma valued at 30x FY22 EPS. The IPO, which is completely an offer for sale (OFS), will close tomorrow. The price band is at Rs 1024-1080 and investors can bid for 13 shares in one lot. Nine brokerages have given "subscribe" recommendations to the issue, with some of them seeing the potential in the long term. Analysts say the growth opportunities outweigh the concerns around not-so-cheap valuations. Mankind Pharma is the fourth-largest Indian pharmaceutical company in terms of domestic sales and third largest in terms of sales volume for moving annual total as of December 2022. It has a pan-India marketing presence and operates 25 manufacturing facilities across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D centre with four units located at IMT Manesar, Gurugram and Thane. At the higher end of the price band, the shares o...

Mankind Pharma IPO: After closure of three days subscription on 27th April 2023, investors and market observers are eager waiting for Mankind Pharma IPO allotment date, which is most likely on 3rd May 2023. As per the Mankind Pharma IPO subscription status, the public issue received rave response from the QIB segment investors but it failed to get fully subscribed in retail segment. However, grey market is undeterred by these developments as secondary market has been in bull trend for last six straight sessions. Mankind Pharma IPO GMP today Market observers said that despite Mankind Pharma IPO failed to get subscribed 100 per cent in retail portion, strong secondary market mood has lifted the morale of grey market. Mankind Pharma IPO grey market premium (GMP) today is ₹85, which is ₹25 higher from its Friday GMP of ₹60. They said that uptrend in Mankind Pharma IPO GMP can be expected further when market opens on Monday as secondary market is in highly bullish mode as all three key benchmark indices — Nifty, Sensex and Bank Nifty — have breached their recent swing high levels and they are expected to lift the moral of unlisted stock market as well. What this GMP mean? Market observers went on to add that ₹85, which means grey market is expecting that Mankind Pharma IPO listing price would be around ₹1145 ( ₹1080 + ₹85), which is near 8 per cent higher from Mankind Pharma IPO price band of ₹10286 to ₹1080 per equity share. Market observers maintained that grey market is sign...